Rock Creek Pharmaceuticals, Inc. (RCPIQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rock Creek Pharmaceuticals, Inc. (RCPIQ) trades at $0.0001. Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company focused on therapies for chronic inflammatory diseases and neurologic disorders. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for RCPIQ: RCPIQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RCPIQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on RCPIQ.
How is this calculated? →Rock Creek Pharmaceuticals, Inc. (RCPIQ) Healthcare & Pipeline Overview
Rock Creek Pharmaceuticals, Inc. is a biotechnology firm specializing in the development of Anatabine citrate, a novel anti-inflammatory compound, targeting chronic inflammatory diseases and neurological disorders. Despite its innovative approach, the company navigates a competitive landscape with established pharmaceutical giants and the inherent risks of early-stage drug development.
What Is the Investment Thesis for RCPIQ?
Rock Creek Pharmaceuticals, Inc. presents a high-risk, high-reward investment profile due to its focus on Anatabine citrate, a novel anti-inflammatory compound. The potential success of Anatabine citrate in treating chronic inflammatory diseases and neurologic disorders is a key value driver. However, the company's Chapter 7 liquidation filing in 2016 raises significant concerns about its financial viability and ability to continue operations. Investors should carefully consider the risks associated with investing in a company undergoing liquidation and the uncertainties surrounding the future of Anatabine citrate's development.
Based on FMP financials and quantitative analysis
RCPIQ Key Highlights
Lead compound Anatabine citrate targets chronic inflammatory diseases and neurologic disorders.
- Anatabine citrate's mechanism of action is distinct from existing anti-inflammatory drugs.
- Filed for Chapter 7 liquidation in September 2016, indicating significant financial distress.
- Headquartered in Sarasota, Florida, with a small team of 5 employees.
- Formerly known as Star Scientific, Inc., rebranded in June 2014.
Who Are RCPIQ's Competitors?
RCPIQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HOPHF Hemogenyx Pharmaceuticals Plc | $2.33 | +0.00% | $15.8M | 52 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RCPIQ's Key Strengths?
Novel anti-inflammatory compound (Anatabine citrate).
- Potential for a unique mechanism of action.
- Focus on underserved markets (chronic inflammatory diseases and neurologic disorders).
What Are RCPIQ's Weaknesses?
Chapter 7 liquidation filing.
- Limited financial resources.
- Small team and infrastructure.
- OTC listing indicates higher risk.
What Could Drive RCPIQ Stock Higher?
Potential for restructuring and reorganization following Chapter 7 proceedings.
- Continued research and development of Anatabine citrate.
- Efforts to secure partnerships or licensing agreements.
What Are the Key Risks for RCPIQ?
Chapter 7 liquidation poses a significant threat to the company's survival.
- Limited financial resources hinder development and commercialization efforts.
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval processes.
- OTC listing increases risk and volatility.
What Are the Growth Opportunities for RCPIQ?
- Potential for Anatabine Citrate: If Rock Creek Pharmaceuticals can overcome its financial challenges, the unique mechanism of action of Anatabine citrate could present a significant growth opportunity. The market for anti-inflammatory drugs is substantial, estimated at billions of dollars annually, and a novel treatment option could capture a significant share. However, the company's current financial state casts doubt on its ability to capitalize on this opportunity.
- Partnerships and Licensing: Rock Creek Pharmaceuticals could explore partnerships or licensing agreements with larger pharmaceutical companies to advance the development and commercialization of Anatabine citrate. This would provide access to funding and expertise, mitigating some of the risks associated with drug development. However, the company's bankruptcy filing may make it difficult to attract potential partners.
- Focus on Specific Indications: Rock Creek Pharmaceuticals could focus its efforts on specific indications where Anatabine citrate has shown the most promise. This would allow the company to streamline its development efforts and potentially accelerate the path to regulatory approval. However, this strategy would also narrow the potential market for the drug.
- Restructuring and Reorganization: A successful restructuring and reorganization could provide Rock Creek Pharmaceuticals with a fresh start and the opportunity to rebuild its business. This would require addressing the company's financial challenges and developing a viable business plan. However, the outcome of the bankruptcy proceedings is uncertain.
- Intellectual Property Protection: Maintaining and strengthening intellectual property protection for Anatabine citrate is crucial for the company's long-term success. This would create a barrier to entry for competitors and enhance the value of the drug. However, the company's financial difficulties may make it challenging to protect its intellectual property.
What Threats Does RCPIQ Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval processes.
- Patent expiration and generic competition.
- Failure to secure funding or partnerships.
What Are RCPIQ's Competitive Advantages?
- Proprietary compound: Anatabine citrate's unique mechanism of action.
- Intellectual property: Patents protecting Anatabine citrate.
- First-mover advantage: Potential to be a novel treatment option.
What Does RCPIQ Do?
Rock Creek Pharmaceuticals, Inc., formerly known as Star Scientific, Inc., was renamed in June 2014 and is dedicated to discovering, developing, and commercializing therapies for chronic inflammatory diseases and neurologic disorders. The company's primary focus is Anatabine citrate, a small molecule, cholinergic agonist that exhibits anti-inflammatory pharmacological characteristics. This compound's mechanism of action is distinct from existing anti-inflammatory drugs like biologics, steroids, and non-steroidal anti-inflammatories. Headquartered in Sarasota, Florida, Rock Creek Pharmaceuticals aimed to provide alternative treatment options for patients suffering from these conditions. However, on September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware, impacting its operational capabilities and future prospects.
What Products and Services Does RCPIQ Offer?
- Discovers and develops therapies for chronic inflammatory diseases.
- Focuses on treatments for neurologic disorders.
- Develops Anatabine citrate, a small molecule, cholinergic agonist.
- Aims to commercialize novel anti-inflammatory drugs.
- Seeks to provide alternatives to biologics, steroids, and NSAIDs.
How Does RCPIQ Make Money?
- Develops pharmaceutical products for licensing or commercialization.
- Focuses on research and development of novel therapies.
- Aims to generate revenue through drug sales or partnerships.
What Industry Does RCPIQ Operate In?
Rock Creek Pharmaceuticals, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical companies. The market for anti-inflammatory drugs is substantial, driven by the prevalence of chronic inflammatory diseases. However, the company's bankruptcy filing and OTC listing highlight the challenges faced by smaller biotechnology firms in securing funding and navigating the complex regulatory landscape.
Who Are RCPIQ's Key Customers?
- Patients suffering from chronic inflammatory diseases.
- Patients with neurologic disorders.
- Pharmaceutical companies seeking to license novel therapies.
Company Profile
Rock Creek Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sarasota, US. The company is led by CEO Michael John Mullan MBBS (M.D.,),. RCPIQ has traded publicly since 1998.
RCPIQ Financials
Bull Case vs Bear Case
Bull Case
- Novel anti-inflammatory compound (Anatabine citrate).
- Potential for a unique mechanism of action.
- Focus on underserved markets (chronic inflammatory diseases and neurologic disorders).
- Upcoming: Potential for restructuring and reorganization following Chapter 7 proceedings.
Bear Case
- Chapter 7 liquidation filing.
- Limited financial resources.
- Small team and infrastructure.
- OTC listing indicates higher risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RCPIQ Latest News
No recent news available for RCPIQ.
RCPIQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RCPIQ.
Price Targets
Wall Street price target analysis for RCPIQ.
RCPIQ MoonshotScore
What does this score mean?
The MoonshotScore rates RCPIQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael John Mullan MBBS (M.D.,)
Unknown
Michael John Mullan MBBS (M.D.,) leads Rock Creek Pharmaceuticals, Inc., managing a small team of five employees. His medical background likely informs the company's focus on developing therapies for chronic inflammatory diseases and neurologic disorders. However, information regarding his specific career history, education, and previous roles is not available.
Track Record: Due to the limited information available, it is difficult to assess Michael John Mullan's track record at Rock Creek Pharmaceuticals, Inc. The company's Chapter 7 liquidation filing suggests significant challenges during his tenure. Specific achievements, strategic decisions, and company milestones under his leadership are unknown.
RCPIQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rock Creek Pharmaceuticals, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often face significant challenges related to liquidity, transparency, and regulatory compliance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same listing standards, which can increase the risk for investors.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher risk of fraud or manipulation.
- Potential for delisting or suspension of trading.
- Uncertainty regarding the company's future operations.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their experience.
- Review the company's business plan and prospects.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings.
- Confirm the company's registration and compliance status.
- Focus on pharmaceutical development.
- Development of Anatabine citrate.
- Prior history as a publicly traded company (Star Scientific, Inc.).
What Investors Ask About Rock Creek Pharmaceuticals, Inc. (RCPIQ) — Healthcare
What does Rock Creek Pharmaceuticals, Inc. do?
Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company focused on identifying, developing, and commercializing therapies for chronic inflammatory diseases and neurologic disorders. Their primary asset is Anatabine citrate, a small molecule cholinergic agonist with anti-inflammatory properties.
What do analysts say about RCPIQ stock?
Given Rock Creek Pharmaceuticals, Inc.'s OTC listing and Chapter 7 liquidation filing, formal analyst coverage is unlikely. The company's financial distress and uncertain future make traditional valuation metrics difficult to apply. Any investment decision should be based on a thorough understanding of the risks involved and the potential for a successful restructuring or the development of Anatabine citrate by another entity.
What are the main risks for RCPIQ?
The primary risk for Rock Creek Pharmaceuticals, Inc. is its Chapter 7 liquidation filing, which indicates significant financial distress and raises concerns about the company's ability to continue operations. Other risks include limited financial resources, competition from established pharmaceutical companies, regulatory hurdles, and the inherent uncertainties of drug development. The OTC listing also increases risk due to lower liquidity and disclosure requirements.
What are the key factors to evaluate for RCPIQ?
Evaluate RCPIQ on fundamentals, analyst consensus, and risk factors. Rock Creek Pharmaceuticals, Inc. presents a high-risk, high-reward investment profile due to its focus on Anatabine citrate, a novel anti-inflammatory compound. Not financial advice.
How frequently does RCPIQ data refresh on this page?
RCPIQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RCPIQ's recent stock price performance?
Rock Creek Pharmaceuticals, Inc. (RCPIQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel anti-inflammatory compound (Anatabine citrate). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RCPIQ overvalued or undervalued right now?
Rock Creek Pharmaceuticals, Inc. (RCPIQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RCPIQ before investing?
Before investing in Rock Creek Pharmaceuticals, Inc. (RCPIQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC status and Chapter 7 liquidation filing.
- Financial data may not be readily available or reliable.